-
1.发明授权관중으로부터 얻은 지방산 생합성 효소 저해용플로르글루시놀계 화합물 및 이를 유효성분으로 포함하는암 및 비만 예방과 치료용 조성물 有权FAS抑制化合物来自Dryopteris crassirhiza和用于治疗和预防癌症和肥胖的组合物，其含有与活性成分相同的组合物
公开(公告)号：KR101232993B1
公开(公告)日：2013-02-13
申请号：KR1020060068578
申请日：2006-07-21
IPC: C07C49/703 , C07C49/603 , C07C49/403
Abstract: 본 발명은 관중 유래의 지방산 생합성 효소 (fatty acid synthase, FAS) 저해용 플로르글루시놀계 화합물 및 이를 유효성분으로 포함하는 암 및 비만 예방과 치료용 조성물에 관한 것으로, 관중을 에탄올 추출한 후 크로마토그래피를 이용하여 순수 분리 정제하여 얻은 FAS 저해 화합물과 이를 유효성분으로 함유하는 암 및 비만의 예방과 치료 용도에 관한 것이다.
관중, 지방산 생합성 효소 (FAS), 암, 비만, 플로르글루시놀계 화합물, 에탄올 추출-
公开(公告)号：KR101018819B1
公开(公告)日：2011-03-04
申请号：KR1020087019182
申请日：2007-02-14
Applicant: (주)아모레퍼시픽
IPC: A61K31/17 , A61K31/765 , A61P17/00
CPC classification number: A61K9/0014 , A61K31/17 , A61K47/10 , A61K47/12 , A61K47/20 , A61K47/26 , A61K47/32
Abstract: 본 발명은 바닐로이드 수용체 길항제로서 티오우레아 유도체와 약제학적으로 허용가능한 담체를 함유하는 외용제 조성물 및 이의 약제학적 용도에 관한 것이다.
본 발명의 외용제 조성물은 피부투과와 안정성에서 우수하며 소양성 또는 자극성 피부질환에 유용하다.-
3.发明授权2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ＳＰＣ 수용체 활성으로 유발되는 염증관련 질환치료제 有权新的2,4,5-三唑-3-基噻唑衍生物及其药物可接受的盐，其制备方法，用于由含有2,4,5-三唑基-1,3-噻唑衍生物的SPC活性诱导的抗炎性疾病的治疗剂 有效的成分
公开(公告)号：KR100903974B1
公开(公告)日：2009-06-25
申请号：KR1020070097553
申请日：2007-09-27
Inventor： 공영대 , 조희영 , 전문국 , 이태호 , 최길돈 , 공재양 , 정대영 , 황순희 , 김정주 , 이창훈 , 고재영 , 노민수 , 한은실 , 김형준 , 김혁 , 윤준원 , 모주현 , 김도훈
IPC: C07D277/44 , C07D417/04 , C07D417/12 , A61K31/426
CPC classification number: C07D277/46 , C07D417/04 , C07D417/12
Abstract: 본 발명은 하기 화학식 1로 표시되는 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용 가능한 그의 염, 그의 제조방법 및 그를 유효성분으로 함유하는 SPC 수용체 활성으로 유발되는 염증관련 질환에 유용한 그의 용도에 관한 것이다.
본 발명의 2,4,5-삼중치환-1,3-티아졸 유도체는 사람으로부터 유래된 진피세포 및 마우스를 이용한 동물실험을 통하여 항염증 효과를 검색한 결과, SPC 수용체에 대한 우수한 억제활성을 규명함으로써, 상기 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용 가능한 그의 염을 유효성분으로 함유하여 SPC 수용체 활성으로 유발되는 아토피성 피부염, 기타 질환에서 나타나는 염증, 소양증 또는 피부 감염증에 유효한 염증관련 질환 치료제로서 유용하게 활용될 수 있다.
(상기 식에서, R
1 , R
2 , 및 R
3 는 명세서에서 정의한 바와 같다.)
1,3-티아졸, 스핀고실포스포릴콜린, 아토피 피부염, 염증치료제-
4.发明公开3-클로로-5-치환-퀴녹살린-2-아민 유도체 및 약제학적으로허용 가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ＳＰＣ 수용체 활성으로 유발되는 염증관련 질환치료제 有权新型3-氯代-5-取代的喹喔啉-2-胺衍生物及其药学上可接受的盐，其制备方法，用于由含有3-氯代喹喔啉-2-胺衍生物的SPC活性诱发的抗炎性疾病的治疗剂 有效的成分
公开(公告)号：KR1020090032373A
公开(公告)日：2009-04-01
申请号：KR1020070097554
申请日：2007-09-27
Inventor： 공영대 , 조희영 , 전문국 , 이태호 , 최길돈 , 공재양 , 박우규 , 황순희 , 김정주 , 이창훈 , 고재영 , 노민수 , 한은실 , 김혁 , 윤준원 , 모주현 , 김도훈
IPC: C07D401/12 , A61K31/498 , A61P29/00
CPC classification number: C07D401/12
Abstract: Provided is a 3-chloro-5-substituted-quinoxaline-2-amine derivative and a therapeutic agent using the 3-chloro-5-substituted-quinoxaline-2-amine derivative so as to treat diseases associated with inflammation. A 3-chloro-5-substituted-quinoxaline-2-amine derivative is represented by the formula 1. In the formula 1, R∧1 indicates hydrogen, linear or branched C1-C10 alkyl group, C1-C10 alkoxy group or halogen; R∧2 shows linear or branched C1-C10 alkyl group, C1-C10 alkoxy group, hydroxyl group, halogen group, amine group or substituted amine group, amide group, carbamate group or urea group. In the formula 1, the substituted group indicates a substituted phenyl group wherein one or four groups selected from the group consisting of a linear or branched C1-C10 alkyl group, halogen, nitro group, C1-C10 alkyl group, C1-C10 alkoxy group and C1-C10 haloalkyl group are substituted.
Abstract translation: 本发明提供3-氯-5-取代喹喔啉-2-胺衍生物和使用3-氯-5-取代喹喔啉-2-胺衍生物的治疗剂，以治疗与炎症相关的疾病。 3-氯-5-取代喹喔啉-2-胺衍生物由式1表示。在式1中，R 1表示氢，直链或支链C 1 -C 10烷基，C 1 -C 10烷氧基或卤素; R 2表示直链或支链C 1 -C 10烷基，C 1 -C 10烷氧基，羟基，卤素基，胺基或取代胺基，酰胺基，氨基甲酸酯基或脲基。 在式1中，取代基表示取代的苯基，其中选自直链或支链C 1 -C 10烷基，卤素，硝基，C 1 -C 10烷基，C 1 -C 10烷氧基中的一个或四个基团 和C 1 -C 10卤代烷基被取代。
-
公开(公告)号：KR1020090030497A
公开(公告)日：2009-03-25
申请号：KR1020070095848
申请日：2007-09-20
Applicant: (주)아모레퍼시픽
Abstract: A signal peptide targeting to nucleus is provided to move signal peptide to nucleus through the fusion of the signal peptide and to perform function of heterologous protein in nucleus. An expression vector comprises a gene coding the signal peptide of SEQ ID NO:1 and a gene coding heterologous protein. The heterologous protein is an orphan receptor or steroid receptor response element binding protein 1(SREBP1). The orphan receptor is retinoic acid receptor(RAR), peroxisome proliferator-activated receptor(PPAR) or Liver X receptor(LXR).
Abstract translation: 提供靶向细胞核的信号肽，以通过信号肽的融合将信号肽移动到细胞核，并在细胞核中进行异源蛋白质的功能。 表达载体包含编码SEQ ID NO：1的信号肽的基因和编码异源蛋白质的基因。 异源蛋白是孤儿受体或类固醇受体反应元件结合蛋白1（SREBP1）。 孤儿受体是视黄酸受体（RAR），过氧化物酶体增殖物激活受体（PPAR）或肝X受体（LXR）。
-
Patent Agency Ranking
公开(公告)号：KR1020090030070A
公开(公告)日：2009-03-24
申请号：KR1020070095389
申请日：2007-09-19
Applicant: (주)아모레퍼시픽
Abstract: A signal peptide targeting to lipid droplet for targeting a heterologous protein to lipid droplet is provided to cure and prevent lipid droplet-related diseases containing obesity, diabetes and arteriosclerosis. An expression vector comprises a gene coding signal peptide of SEQ ID NO:1 and a gene coding heterologous protein. The heterologous protein is the lipase or protein kinase A(PKA). The composition for targeting a heterologous protein to lipid droplet comprises the expression vector.
Abstract translation: 提供靶向脂滴以将异源蛋白质靶向脂质液滴的信号肽，以治愈和预防含有肥胖，糖尿病和动脉硬化的脂滴相关疾病。 表达载体包含SEQ ID NO：1的基因编码信号肽和编码异源蛋白质的基因。 异源蛋白是脂肪酶或蛋白激酶A（PKA）。 将异源蛋白质靶向脂滴的组合物包含表达载体。
-
公开(公告)号：KR1020080051201A
公开(公告)日：2008-06-11
申请号：KR1020060121861
申请日：2006-12-05
Applicant: (주)아모레퍼시픽
IPC: A61K31/685 , A61K31/661
CPC classification number: A61K31/688 , Y10S514/863 , Y10S514/886
Abstract: A pharmaceutical composition comprising sphingosylphosphorylcholine or derivatives thereof is provided to inhibit proliferation and promote differentiation of keratinocyte, inhibit proliferation of splenocyte and T cell, induce reduction of leucocyte, and reduce mouse ear swelling induced by TPA(tetradecanoyl phorbol acetate), so that the composition is useful for treating psoriasis. A pharmaceutical composition for treating psoriasis comprises sphingosylphosphorylcholine(SPC) represented by the formula(1) or derivatives thereof and is formulated as tablet, pill, powder, sachet, elixir, suspension, emulsion, solution, syrup, aerosol, soft or hard gelatin capsule, sterile injection or sterile powder, wherein the daily dosage is 1-100 mg/kg, preferably 5-70 mg/kg.
Abstract translation: 提供包含鞘氨醇磷酰胆碱或其衍生物的药物组合物，以抑制角质形成细胞的增殖和促进分化，抑制脾细胞和T细胞的增殖，诱导白细胞的减少，并减少TPA（十四酰基佛波醇乙酸酯）诱导的小鼠耳肿胀，使组合物 可用于治疗牛皮癣。 用于治疗牛皮癣的药物组合物包含由式（1）表示的鞘糖基磷酰胆碱（SPC）或其衍生物，并配制成片剂，丸剂，粉末，小药囊，酏剂，悬浮液，乳剂，溶液，糖浆，气雾剂，软或硬明胶胶囊 无菌注射或无菌粉末，其中日剂量为1-100mg / kg，优选5-70mg / kg。
-
公开(公告)号：KR1020080006961A
公开(公告)日：2008-01-17
申请号：KR1020060066357
申请日：2006-07-14
IPC: A61K9/70
CPC classification number: A61K9/7038 , A61K31/192 , A61K31/196
Abstract: A transdermal preparation is provided to promote the drug absorption by the skin hydration through a hydrophobic adhesive layer, show continuous and high effect of a drug by maintaining the thermodynamic activity of the hydrophobic drug in an adhesive caused by moisture discharged from skin and be able to reduce the cost and the time due to a very simple preparing process. A transdermal preparation for a hydrophobic drug comprises a supportive layer(1) which is the uppermost portion of a layered structure and has the elasticity; a hydrophobic adhesive layer(2) which is layered under the supportive layer and prevents the loss of moisture absorbed from skin and the reverse conversion of the drug; and a drug containing adhesive layer(3) which is layered under the hydrophobic adhesive layer, includes a drug and attaches the transdermal preparation to the skin and is characterized in that the drug adhesive layer includes a hydrophobic drug such as a non-steroidal antiphlogistics and an absorption promoting agent, where a hydrophobic adhesive of the hydrophobic adhesive layer is selected from the group consisting of polyisobutylene adhesive, styrene-isoprene-styrene adhesive, and styrene-butadiene-styrene adhesive, the drug containing adhesive layer is an acrylate polymer made from acrylate, hydroxypropyl acrylate, acrylamide, acrylamide vinyl acetate, vinyl derivative, methacrylate, hydroxypropyl methacrylate and methacrylamide. The preparation further comprises a release layer(4) which is layered under the drug adhesive layer and protects the drug adhesive layer before use.
Abstract translation: 提供透皮制剂以通过疏水粘合剂层通过皮肤水合促进药物吸收，通过将疏水药物的热力学活性保持在由皮肤排出的水分引起的粘合剂中，显示出药物的连续和高效果，并且能够 由于非常简单的准备过程，降低了成本和时间。 用于疏水性药物的透皮制剂包括支撑层（1），其是层状结构的最上部并具有弹性; 疏水性粘合剂层（2），其被层叠在支撑层下方并防止皮肤吸收的水分的损失和药物的逆转换; 和层叠在疏水性粘合剂层下面的药物含有粘合剂层（3）的药物包含药物，并将透皮制剂附着于皮肤，其特征在于，所述药物粘合剂层包括疏水性药物，例如非甾体消炎药， 吸水促进剂，其中疏水性粘合剂层的疏水性粘合剂选自聚异丁烯粘合剂，苯乙烯 - 异戊二烯 - 苯乙烯粘合剂和苯乙烯 - 丁二烯 - 苯乙烯粘合剂，所述药物粘合剂层是由 丙烯酸酯，丙烯酸羟丙酯，丙烯酰胺，丙烯酰胺乙酸乙烯酯，乙烯基衍生物，甲基丙烯酸酯，甲基丙烯酸羟丙酯和甲基丙烯酰胺。 该制剂还包括层叠在药物粘合剂层下面的释放层（4），并在使用前保护药物粘合剂层。
-
公开(公告)号：KR1020080006960A
公开(公告)日：2008-01-17
申请号：KR1020060066353
申请日：2006-07-14
IPC: A61K9/70
CPC classification number: A61K9/7061 , A61K47/32
Abstract: A transdermal preparation is provided to continuously allow a highly concentrated hydrophobic drug to be absorbed into skin until a patch is detached from the skin with minimized skin side effects and provide the enough adhesive capability during the time of exhibiting the medical efficacy by being attached to the skin. A transdermal preparation for a hydrophobic drug comprises a supportive layer(1) which is the uppermost portion of a layered structure and has the elasticity; a hydrophobic adhesive layer(2) which is layered under the supportive layer and prevents the loss of moisture absorbed from skin and the reverse conversion of the drug; and a drug adhesive layer(3) which is layered under the hydrophobic adhesive layer, includes a drug and attaches the transdermal preparation to the skin and is characterized in that the drug adhesive layer includes a hydrophobic drug such as a non-steroidal antiphlogistics and an acryl adhesive agent and the acryl adhesive agent includes a hydrophilic monomer promoting the skin absorption from the skin and is selected from the group consisting of acrylic acid, methyl methacrylate, ethyl acrylate, hydroxyethyl acrylate, butyl acrylate, octyl acrylate, 2-ethylhexyl acrylate, and hexyl acrylate. The preparation further comprises a release layer(4) which is layered under the drug adhesive layer and protects the drug adhesive layer before use.
Abstract translation: 提供透皮制剂以连续地允许高度浓缩的疏水性药物被吸收到皮肤中，直到贴片从皮肤上分离出来，使皮肤的副作用最小化，并且在展示医疗功效的时间期间提供足够的粘合能力， 皮肤。 用于疏水性药物的透皮制剂包括支撑层（1），其是层状结构的最上部并具有弹性; 疏水性粘合剂层（2），其被层叠在支撑层下方并防止皮肤吸收的水分的损失和药物的逆转换; 以及层叠在疏水性粘合剂层下方的药物粘合剂层（3），包括药物，并且将透皮制剂附着于皮肤，其特征在于，所述药物粘合剂层包括疏水性药物，例如非甾体消炎药和 丙烯酸粘合剂和丙烯酸粘合剂包括促进皮肤吸收皮肤的亲水单体，并且选自丙烯酸，甲基丙烯酸甲酯，丙烯酸乙酯，丙烯酸羟乙酯，丙烯酸丁酯，丙烯酸辛酯，丙烯酸2-乙基己酯， 和丙烯酸己酯。 该制剂还包括层叠在药物粘合剂层下面的释放层（4），并在使用前保护药物粘合剂层。
-
公开(公告)号：KR1020080004078A
公开(公告)日：2008-01-09
申请号：KR1020060062567
申请日：2006-07-04
Applicant: (주)아모레퍼시픽
CPC classification number: A61K9/1682 , A61K9/0002 , A61K47/6925 , A61K47/6951
Abstract: A sustained-release porous microparticle for pulmonary delivery of a charged protein drug is provided to rapidly deliver the charged protein drug to epidermal cells in deep part of the lung without macrophage damage, thereby maintaining stability of the protein drug and continuously releasing the protein drug for a long period of time. A sustained-release porous microparticle for pulmonary delivery of a charged protein drug is prepared by (1) solubilizing cyclodextrin derivatives, ionic polysaccharides and a charged protein drug in water to prepare an inner water phase, (2) adding biodegradable polymer into organic solvent to prepare an organic phase, (3) mixing the inner water phase of step (1) with the organic phase of step (2) to prepare a first emulsion, and (4) spraying the first emulsion to an outer aqueous continuous phase containing an aqueous coating material, and has an average particle diameter of 5-100 mum.
Abstract translation: 提供用于肺部递送带电荷的蛋白质药物的持续释放多孔微粒以迅速将带电荷的蛋白质药物递送至深部肺部的表皮细胞而无巨噬细胞损伤，从而保持蛋白质药物的稳定性并连续释放蛋白质药物 很长一段时间。 通过（1）将环糊精衍生物，离子多糖和带电荷的蛋白质药物溶于水中制备内水相制备用于肺部递送带电荷蛋白药物的持续释放多孔微粒，（2）将可生物降解的聚合物加入到有机溶剂中 制备有机相，（3）将步骤（1）的内部水相与步骤（2）的有机相混合以制备第一乳液，和（4）将第一乳液喷雾到含有水相的外部含水连续相中 涂料，平均粒径为5〜100μm。
-
-
-
-
-
-
-
-
-
Search Results
64
records
(took 0.035 seconds)
